Surgical treatment of gastrinomas: a single‐centre experience  by Atema, Jasper J. et al.
ORIGINAL ARTICLE
Surgical treatment of gastrinomas: a single-centre experience
Jasper J. Atema1, Ramzi Amri1, Olivier R. C. Busch1, Erik A. J. Rauws2, Dirk J. Gouma1 & Els J. M. Nieveen van Dijkum1
Departments of 1Surgery and 2Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands
Abstract
Background: Gastrinomas are rare neuroendocrine tumours, and responsible for Zollinger–Ellison
syndrome (ZES). Surgery is the only treatment that can cure gastrinomas. The success of surgical
treatment of gastrinomas in a single centre was evaluated.
Methods: A retrospective review of all patients who underwent resection for a gastrinoma between 1992
and 2011 at a single institution was performed. Presentation, diagnostics, operative management and
outcome were analysed.
Results: Eleven patients with a median age of 46 years were included. All patients had fasting
hypergastrinaemia and a primary tumour was localized using imaging studies in all patients. A pylorus-
preserving pancreaticoduodenectomy was performed in three patients: two patients underwent duo-
denectomy and one patient central pancreatectomy. The remaining five patients underwent enucleation.
A primary tumour was removed in nine patients: five tumours were situated in the pancreas, three in the
duodenum and one patient was considered to have a primary lymph node gastrinoma. The median
follow-up was 3 years (range 1–15) after which 7 patients were disease-free and 3 patients had
(suspected) metastatic disease. One patient died 13 years after initial surgery.
Conclusion: The success of surgical treatment of a gastrinoma in this series was 7/11 with a median
follow-up of 3 years; comparable to recent published studies.
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Introduction
Gastrinomas are rare neuroendocrine tumours with an estimated
incidence of 0.5 to 4/million population/year.1 In 1955, Zollinger
and Ellison described the symptoms of these gastrin-secreting
tumours: the Zollinger–Ellison syndrome (ZES).2 Abdominal pain
as a result of peptic ulcer disease or gastro-esophageal reflux
disease is the most frequent complaint, followed by diarrhoea.3
In only 0.1–1% of patients with peptic ulcers, ZES is the under-
lying cause.1 The diagnosis of ZES should be suspected in patients
with recurrent peptic ulcers, multiple ulcers or ulcers in unusual
locations such as the distal duodenum and proximal jejunum. The
diagnosis is established by measuring fasting gastrin levels after
antisecretory therapy has been discontinued (proton pump
inhibitors 1 week, histamine type-2 receptor antagonists 2 days).4
Other causes of hypergastrinaemia, such as achlorhydria, should
be excluded. Additionally, a secretin-stimulation test should be
performed.5
In about 75% of patients the tumours are sporadic. Twenty-five
per cent of patients have gastrinomas as part of multiple endo-
crine neoplasia type-1 (MEN-1); a syndrome characterized by the
combined occurrence of primary hyperparathyroidism, duodeno-
pancreatic endocrine neoplasms and tumours of the anterior
pituitary gland.6
The gastric hypersecretion of ZES can generally be treated
effectively with antisecretory medication.7 However, surgery is the
only known curative treatment for gastrinomas.5,8
The aim of this study was to present and evaluate a tertiary
referral centre’s 20-year experience in the surgical management of
gastrinomas.
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Patients and methods
Patients referred to a single institution for surgical assessment
and treatment of gastrinomas were selected from a prospective
database containing patients with pancreatic and periampullary
tumours between January 1992 and December 2011. Additionally,
histopathological diagnoses of gastrinomas were collected using
the histopathology archive PALGA (‘Pathologisch Anatomisch
Landelijk Geautomatiseerd Archief ’; nationwide database for
pathologic specimens). Only patients with pre-operative symp-
toms of ZES were included. Patients with neuroendocrine
tumours immunohistochemical positive for gastrin but without
evidence of ZES were excluded; these tumours should be consid-
ered non-functional NETs expressing gastrin.
Data concerning clinical presentation, time to diagnosis, pre-
operative diagnostic techniques and type of surgery were studied;
peri-operative mortality, morbidity and overall survival were cal-
culated. Follow-up information was collected through medical
records and telephone interviews with general practitioners.
The primary outcome measure of the study was success of
surgical treatment (disease-free survival), defined as normalized
serum gastrin levels and absent signs of recurrent or metastatic
disease on imaging. Secondary outcomes measures were surgical
morbidity and the post-operative use of drugs to control gastric
hypersecretion.
Results
A total of 11 patients was indentified; 4 women and 7 men
(Table 1). The median age was 46 years (range 73–69). Abdominal
pain as a result of peptic ulcer disease was the most frequent
complaint (9 of 11) follow by diarrhoea (5 of 11). Four patients
developed complicated ulcer disease before the diagnosis of ZES
was made. One patient presented with hypovolemic shock as a
result of perforation of a duodenal ulcer.9 The median delay
between onset of symptoms and the diagnosis of ZES was 8 years
(range 1–17). One patient had ZES as part of MEN 1 syndrome.
Pre-operative diagnostics
In all patients the diagnosis of ZES had been established by meas-
uring fasting gastrin levels. The mean serum gastrin level was
1251 ng/l (range 165–5750, normal range 0–130). A secretin
stimulation test was performed in two patients. Combined con-
ventional imaging studies [computed tomography (CT), mag-
netic resonance imaging (MRI) and ultrasound (US)] were able to
successfully locate the gastrinoma in ten patients. Somatostatin
receptor scintigraphy (SRS) was performed using [111In-DTPA-D-
Phe1]-octreotide in all patients and was combined with single-
photon emission computed tomography (SPECT)/CT with the
exception of the first two patients. Imaging of the primary tumour
and/or metastasis using SRS was successful in all patients (Fig. 1).
Four patients had suspected lymph node metastases. One patient
had a suspected neuroendocrine tumour metastasis in the right
lung.
Operative procedures
The decision on type of surgery was made pre- or peri-operatively
based on tumour localization and size. Tumours located in the
pancreas were enuclated if possible. A central or distal pancreate-
ctomy was performed when a tumour, located in the neck, body or
tail, was embedded deep in the pancreatic tissue. A pancreati-
coduodenectomy was performed in patients with a large pancre-
atic head or duodenal tumour that could not be enucleated and in
patients with multiple lymph nodes with a duodenal or pancreatic
head tumour.
An intra-operative ultrasound (IOUS) was performed in five
patients. Three patients underwent a pylorus-preserving pancrea-
ticoduodenectomy (PPPD) (Table 2). In one patient an enuclea-
tion had been performed before a PPPD; only lymph node
Table 1 Clinical characteristic of 11 patients undergoing surgical resection for a gastrinoma
Patient Gender Age (years) Symptoms Time from onset disease
to diagnosis (years)
Serum gastrin (ng/l)
1 M 44 Pain, diarrhoea 15 2000
2 F 43 Pain 10 650
3 F 59 Hypovolemic shock as a result of bleeding ulcer 1 5750
4 M 43 Pain 17 610
5 F 44 Pain, diarrhoea 6 1650
6 M 59 Pain 5 165
7 M 69 Diarrhoea 8 600
8 M 37 Pain, diarrhoea 1 356
9a M 61 Pain 11 300
10 M 46 Pain 4 285
11 F 56 Pain, diarrhoea 10 1400
aMEN 1 patient.
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metastases were resected. Post-operative imaging located the
primary tumour and a subsequent PPPD was performed. The
post-operative course after PPPD was complicated in one of three
patients; this patient had portal vein thrombosis for which anti-
coagulation therapy was subsequently administered for a course
of 6 months. One patient underwent a central pancreatectomy.
Two patients underwent a duodenectomy, of which one developed
post-operative delayed gastric emptying requiring total parenteral
nutrition. The remaining five patients underwent enucleation. In
one of these five patients the post-operative course was compli-
cated by the development of abdominal chyle leakage which was
treated by percutaneous drainage and a medium-chain triglycer-
ide diet.
Pathology
In 3 of the 11 patients the gastrinoma was located in the duode-
num. Five patients had primary tumours located in the pancreas;
three were situated in the pancreatic head and two in the body.
Furthermore, pathological examination of the specimens showed
lymph node involvement in five patients (median number of
lymph nodes evaluated; 4, range 2–12). Of these patients, two
had lymph node involvement (1 and 3 lymph nodes) without an
identifiable primary tumour, in spite of extensive intra-operative
exploration and imaging. One patient, to whom resection was
proposed, underwent a duodenectomy elsewhere. The primary
tumour could not be identified in the resected tissue. Of the
successfully located gastrinomas, one was classified as a well-
differentiated endocrine tumour of uncertain behaviour accord-
ing to the WHO classification.10 The remaining tumours were
well-differentiated endocrine carcinomas with low-grade malig-
nant behaviour.
Follow-up and outcome
Follow-up consisted of yearly evaluation with biochemical studies
(gastrin and chromogranin A). Imaging studies were not routinely
performed.
After PPPD, two of the three patients remained disease-free
during a follow-up of 1 and 7 years. The third patient, who under-
went PPPD, had a gastrinoma as part of MEN-1 syndrome.
During the 3-year follow-up, this patient has elevated fasting
serum gastrin levels and imaging was not able to localize recurrent
tumours or lymph node metastases. Symptomatic control has
been achieved with proton pump inhibition.
After a duodenectomy, one of the two patients, with the sus-
pected lesion in the lung, showed no biochemical signs of disease
up to date (a follow-up period of 1 year). Further investigation of
the lung has yet to be performed. In the other patient, who under-
Figure 1 A transverse 111In-octreotide single-photon emission com-
puted tomography (SPECT)/CT image showing a paraduodenal
‘hotspot’
Table 2 Operative procedures and outcome in 11 patients with a gastrinoma
Patient Type of surgery Localization of a gastrinoma Lymph node
metastases
Follow-up (years) Outcome
1 Enucleation Pancreas - 15 Disease free
2 Enucleation Duodenum - 13 Disease free
3 Enucleation Failed to localize primary + 5 Metastatic disease
Symptomatic treatment of ZES
4 Enucleation Pancreas - 1 Disease free
5 Enucleation Lymph node primary - 1 Disease free
6 Duodenectomy Failed to localize - 2 Symptomatic treatment of ZES
7 Duodenectomy Duodenum - 1 Disease free
8 Central pancreatectomy Pancreas - 13 Died of metastatic disease
9a PPPD Pancreas + 3 Suspected recurrence
10 PPPDb Pancreas + 7 Disease free
11 PPPD Duodenum + 1 Disease free
aMEN 1 patient.
bEnucleation performed before PPPD.
PPPD, pylorus-preserving pancreaticoduodenectomy; ZES, Zollinger–Ellison syndrome.
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went duodenectomy elsewhere without removal of the gastri-
noma, imaging studies repeatedly failed to localize the primary
tumour. During 3 years of follow-up, symptoms of gastric hyper-
secretion were successfully treated with proton pump inhibitors.
Three of five patients treated with an enucleation are free of
disease after a follow-up of 1, 13 and 15 years. Antisecretory
therapy by means of proton pump inhibitors is being continued in
two patients. One patient developed recurrent lymphatic meta-
static disease after removal of lymph node metastases without an
identifiable primary tumour. Because symptoms are relatively
subtle and well controlled by proton pump inhibition, and the
patient has severe comorbidity, no further treatment is being
planned. In the fifth patient who underwent enucleation, only a
single lymph node containing a gastrinoma was removed without
an identifiable primary tumour (Fig. 2). The patient has normal-
ized serum gastrin levels and no evidence of recurrent or meta-
static disease after 1 year of follow-up. Therefore, this patient is
considered to have a primary gastrinoma of a lymph node.11
The patient who underwent a central pancreatectomy devel-
oped hepatic metastases after 5 years and a hemihepatectomy was
subsequently performed. As a result of recurrent hepatic metas-
tases, the patient was treated with multiple resections, radiofre-
quency ablations (RFA) and treatments with radiolabelled
somatostatin analogues. The patient died of metastatic disease
13 years after initial surgery.
Discussion
In this study the results of surgical treatment of gastrinomas in a
single centre are described. Only 11 patients were operated over a
period of 19 years. The low incidence as well as the successful
symptomatic treatment with antisecretory medication might be
partially responsible for low referral numbers.12
The median delay between the onset of symptoms and the
diagnosis of ZES in this study was 8 years (range 1–17). Previously
published data show a typical delay in the diagnosis of 5 to
9 years.3 Patients are frequently being misdiagnosed before the
diagnosis of ZES is properly established. Conventional imaging
was able to localize the tumour in 10 out of 11 patients. However,
numerous studies describe a negative result of conventional
imaging in approximately one-third of patients with sporadic
gastrinomas.1 Pre-operative somatostatin receptor scintigraphy
(SRS) was positive in all patients. Correspondingly, data suggests
SRS is more sensitive than conventional localization studies com-
bined (CT, MRI and US) for localizing both primary tumours and
metastases.13 The positive results of this study regarding imaging
might be explained by selection bias; perhaps only patients with a
localized tumour were referred for surgical treatment.
During exploration and IOUS, the primary tumour was suc-
cessfully indentified in 9 out of 11 patients. The sensitivity of
palpation and IOUS are 91% and 95%, respectively.1 Of the suc-
cessfully localized tumours, seven were located in the so-called
gastrinoma triangle, an anatomic triangle which includes the
duodenum, the pancreatic head and the hepatoduodenal ligament
(Fig. 3).14 Approximately 70–85% of all gastrinomas are located in
the gastrinoma triangle.15,16 Duodenal tumours comprise 50–88%
of sporadic gastrinomas and 70–100% of gastrinomas as part of
MEN 1.15 The possible presence of lymph node primary gastrino-
mas in patients with ZES remains a controversial subject.
However, numerous studies strongly support the notion that
lymph node primary tumours exist and might account for
approximately 10% of sporadic gastrinomas.11
In this study, five patients had lymph node involvement at the
time of surgery, either as lymph node metastases or as a suspected
lymph node primary gastrinoma. Even although most gastrino-
mas grow slowly, 50–70% have lymph node involvement at the
time of diagnosis.1,17 Furthermore, 5–10% of duodenal gastrino-
mas and 20–25% of pancreatic gastrinomas are associated with
liver metastases at diagnosis.5
After PPPD, two out of three patients are free of disease. The
remaining patient, with MEN-1 syndrome, had persisting elevated
serum gastrin levels but no identifiable tumour on imaging. Enu-
cleation was successful in four of six patients; one patient under-
went additional surgery and one patient only had multiple lymph
nodes containing a gastrinoma removed without a primary
tumour. A duodenectomy resulted in the successful removal of the
gastrinoma in one of two patients. The patient that underwent a
central pancreatectomy developed hepatic metastases and eventu-
ally died of metastatic disease. Within the limitations of this small
series, the success of surgical treatment of a gastrinoma was 7/11
with a median follow-up of 3 years (range 1–15). Previously pub-
lished studies describe success rates of 50–60% direct postopera-
tively and 25–30% 5–10 years after surgery.1,12
Surgical resection is the only chance of a complete cure of a
gastrinoma.12 It is known to increase survival and reduce the rate
of hepatic metastases.8 Routine surgical exploration should be
performed in all patients with sporadic gastrinomas without evi-
Figure 2 Intra-operative photograph of a patient with a lymph node
containing a gastrinoma near the duodenal wall (arrow)
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dence of diffuse hepatic metastases.5 If possible, pancreatic gastri-
nomas should be enucleated. If the pancreatic body and/or tail
tumours can not be enucleated, a distal pancreatectomy is per-
formed. A pancreaticoduodenectomy is typically reserved for
patients with a large pancreatic head or duodenal tumours that
cannot be enucleated or if the patient has multiple duodenal or
pancreatic head tumours. A duodenotomy should be performed
routinely to detect small duodenal gastrinomas, preferably com-
bined with IOUS.18 A lymph node dissection should be carried
out, even if no primary tumour is found.
Controversy remains regarding routine surgical exploration in
patients with MEN-1/ZES. Disagreement not only exists concern-
ing the indication for surgery but also the type of operation. Some
authors recommend surgery when imaging studies identify
tumours larger than 2–3 cm whereas others advocate a more
aggressive treatment.17
The question whether a pancreaticoduodenectomy should be
more frequently used in the management of ZES remains contro-
versial.17 Several series report a better chance of a cure and
increased survival, especially in patients with MEN 1 syndrome.17
Perhaps in the future a pancreaticoduodenectomy will be recom-
mended in selected patients, especially as the mortality rate after
pancreatic surgery in high-volume centres has decreased to less
than 5%.19,20
In conclusion, this study describes a single-centre’s experience
of the surgical management of gastrinomas with a success rate of
7/11 during a median follow-up of 3 years (range 1–15). Even
although controversies still exist in the management of patients
with ZES, surgery offers the only possible complete cure and plays
an important role in the treatment of gastrinomas. Given the
complex management, every patient with a gastrinoma should be
discussed in a multidisciplinary team consisting of gastroenter-
ologists, endocrinologists, radiologists, nuclear medicine special-
ists and pancreatic- and endocrine surgeons.
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